Broadwing
3 employees on LinkedIn · 1 known investors
Broadwing Bio develops antibody-based therapies targeting genetically validated ophthalmology conditions, particularly geographic atrophy and glaucoma, to preserve vision and prevent blindness. The company builds on naturally occurring genetic variants to create novel treatments for ocular diseases.
Investors · 1
In the news
Frequently asked questions
- What does Broadwing do?
- Broadwing Bio develops antibody-based therapies targeting genetically validated ophthalmology conditions, particularly geographic atrophy and glaucoma, to preserve vision and prevent blindness. The company builds on naturally occurring genetic variants to create novel treatments for ocular diseases.
- Who are Broadwing's investors?
- Broadwing's investors include 82VS.